SG11202008343YA - IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE - Google Patents

IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE

Info

Publication number: SG11202008343YA
Authority: SG; Singapore
Prior art keywords: igm; affect; life; serum half; chain mutations
Prior art date: 2018-03-01

Application number

SG11202008343YA

Inventor

Ramesh Baliga

Bruce Alan Keyt

Dean Ng

Original Assignee

Igm Biosciences Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-03-01

Filing date

2019-03-01

Publication date

2020-09-29

2019-03-01 Application filed by Igm Biosciences Inc filed Critical Igm Biosciences Inc

2020-09-29 Publication of SG11202008343YA publication Critical patent/SG11202008343YA/en

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/526—CH3 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/528—CH4 domain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/624—Disulfide-stabilized antibody (dsFv)
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

Health & Medical Sciences (AREA)
Immunology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Biomedical Technology (AREA)
Urology & Nephrology (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
General Physics & Mathematics (AREA)
Physics & Mathematics (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Food Science & Technology (AREA)
Peptides Or Proteins (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Investigating Or Analysing Biological Materials (AREA)

SG11202008343YA 2018-03-01 2019-03-01 IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE SG11202008343YA (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862637186P	2018-03-01	2018-03-01
PCT/US2019/020374 WO2019169314A1 (en)	2018-03-01	2019-03-01	IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE

Publications (1)

Publication Number	Publication Date
SG11202008343YA true SG11202008343YA (en)	2020-09-29

Family

ID=67805543

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11202008343YA SG11202008343YA (en)	2018-03-01	2019-03-01	IgM Fc AND J-CHAIN MUTATIONS THAT AFFECT IgM SERUM HALF-LIFE

Country Status (12)

Country	Link
US (3)	US10899835B2 (en)
EP (1)	EP3758752A4 (en)
JP (2)	JP7376490B2 (en)
KR (1)	KR102745232B1 (en)
CN (1)	CN111787951B (en)
AU (1)	AU2019227984A1 (en)
BR (1)	BR112020017296A2 (en)
CA (1)	CA3091144A1 (en)
IL (1)	IL276590A (en)
MX (1)	MX2020009069A (en)
SG (1)	SG11202008343YA (en)
WO (1)	WO2019169314A1 (en)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK3105250T3 (en)	2014-02-10	2020-09-28	Igm Biosciences Inc	MULTISPECIFIC IGA BINDING MOLECULES
IL278350B (en)	2014-04-03	2022-06-01	Igm Biosciences Inc	Modified j-chain
KR102435324B1 (en)	2015-01-20	2022-08-23	아이쥐엠 바이오사이언스 인코포레이티드	Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof
KR20230130148A (en)	2015-03-04	2023-09-11	아이쥐엠 바이오사이언스 인코포레이티드	Cd20 binding molecules and uses thereof
KR102558839B1 (en)	2015-03-25	2023-07-25	아이쥐엠 바이오사이언스 인코포레이티드	Multivalent hepatitis B virus antigen-binding molecules and uses thereof
CN107847591B (en)	2015-04-17	2023-07-28	Igm生物科学股份有限公司	Multivalent human immunodeficiency virus antigen binding molecules and uses thereof
CN108463472A (en)	2015-09-30	2018-08-28	Igm生物科学有限公司	The binding molecule of J- chains with modification
JP7065766B2 (en)	2015-09-30	2022-05-12	アイジーエムバイオサイエンシズインコーポレイテッド	Bonded molecule with modified J chain
EP3455257B1 (en)	2016-05-09	2021-09-22	IGM Biosciences Inc.	Anti-pd-l1 antibodies
JP2020512820A (en)	2017-04-07	2020-04-30	アイジーエムバイオサイエンシズインコーポレイテッド	Modified human IgM constant region for regulation of effector function of complement dependent cytolysis
BR112020017296A2 (en)	2018-03-01	2020-12-29	Igm Biosciences, Inc.	CHANGES OF IGM FC AND J CHAIN AFFECTING THE SERUM IGM SERIE LIFE
CA3147291A1 (en)	2019-08-15	2021-02-18	Igm Biosciences, Inc.	Immunostimulatory multimeric binding molecules
CN114341179B (en) *	2019-08-17	2025-01-28	Igm生物科学股份有限公司	Multimeric bispecific anti-CD123 binding molecules and their uses
EP4031252A4 (en) *	2019-09-19	2023-09-13	IGM Biosciences, Inc.	Multimeric antibodies with enhanced selectivity for cells with high target density
CN110669134A (en) *	2019-10-15	2020-01-10	广东菲鹏生物有限公司	IgM-FC fragment, IgM-FC antibody, preparation method and application
MX2022008357A (en) *	2020-01-06	2022-08-04	Igm Biosciences Inc	Highly sialylated multimeric binding molecules.
CN115485299A (en)	2020-04-22	2022-12-16	Igm生物科学股份有限公司	PD-1 agonist multimeric binding molecules
IL297619A (en) *	2020-05-12	2022-12-01	Igm Biosciences Inc	Use of a multimeric anti-dr5 binding molecule in combination with a cancer therapy for treating cancer
US20220033851A1 (en) *	2020-08-03	2022-02-03	Roger B. Swartz	mRNA, episomal and genomic integrated lentiviral and gammaretroviral vector expression of dimeric immunoglobulin A and polymeric immunoglobulin A to Enable Mucosal and Hematological Based Immunity/Protection via Gene Therapy for Allergens, viruses, HIV, bacteria, pneumonia, infections, pathology associated proteins, systemic pathologies, cancer, toxins and unnatural viruses. CAR engineered and non-CAR engineered immune cell expression of dimeric immunoglobulin A and polymeric immunoglobulin A.
WO2022080912A1 (en) *	2020-10-16	2022-04-21	주식회사 아이엠바이오로직스	Fusion protein platform using igm region
US20240400658A1 (en) *	2021-09-13	2024-12-05	Shenyang Eye Industry Technology Institute Ltd.	Anti-periostin humanized monoclonal antibody, and preparation method therefor and use thereof
WO2023064766A1 (en) *	2021-10-11	2023-04-20	Igm Biosciences, Inc.	Lateral flow device and uses thereof
AU2023249803A1 (en)	2022-04-07	2024-11-07	Repertoire Immune Medicines, Inc.	T cell receptor multimers and uses thereof

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0904107B1 (en) *	1996-03-18	2004-10-20	Board Of Regents, The University Of Texas System	Immunoglobin-like domains with increased half lives
US6045774A (en) *	1997-01-10	2000-04-04	Epicyte Pharmaceutical Inc.	J chain polypeptide targeting molecule linked to an imaging agent
US7311912B1 (en) *	1997-01-10	2007-12-25	Plantbodies Corporation	Epithelial tissue targeting agent
US20050129616A1 (en)	2001-05-25	2005-06-16	Human Genome Sciences, Inc.	Antibodies that immunospecifically bind to TRAIL receptors
US20040248299A1 (en)	2002-12-27	2004-12-09	Sumedha Jayasena	RNA interference
US20050014932A1 (en)	2003-05-15	2005-01-20	Iogenetics, Llc	Targeted biocides
DK1814913T3 (en)	2004-11-05	2015-09-28	Univ Leland Stanford Junior	ANTIBODY-INDUCED CELL membrane damage.
CA2605781A1 (en) *	2005-05-09	2007-04-12	Glycart Biotechnology Ag	Antigen binding molecules having modified fc regions and altered binding to fc receptors
EP2313502A4 (en) *	2008-07-14	2012-04-04	Uchicago Argonne Llc	Methods for systematic control of protein stability
NO2486141T3 (en) *	2009-10-07	2018-06-09
KR102102111B1 (en)	2012-02-08	2020-04-20	아이쥐엠 바이오사이언스 인코포레이티드	Cdim binding proteins and uses thereof
EP3689902B1 (en) *	2013-03-15	2023-06-28	Dana-Farber Cancer Institute, Inc.	Flavivirus neutralizing antibodies and methods of use thereof
EP3041862B1 (en)	2013-09-05	2020-05-06	IGM Biosciences, Inc.	Constant chain modified bispecific, penta- and hexavalent ig-m antibodies
DK3105250T3 (en)	2014-02-10	2020-09-28	Igm Biosciences Inc	MULTISPECIFIC IGA BINDING MOLECULES
IL278350B (en)	2014-04-03	2022-06-01	Igm Biosciences Inc	Modified j-chain
KR102435324B1 (en)	2015-01-20	2022-08-23	아이쥐엠 바이오사이언스 인코포레이티드	Tumor necrosis factor (TNF) superfamily receptor binding molecules and uses thereof
KR20230130148A (en)	2015-03-04	2023-09-11	아이쥐엠 바이오사이언스 인코포레이티드	Cd20 binding molecules and uses thereof
KR102558839B1 (en)	2015-03-25	2023-07-25	아이쥐엠 바이오사이언스 인코포레이티드	Multivalent hepatitis B virus antigen-binding molecules and uses thereof
CN107847591B (en)	2015-04-17	2023-07-28	Igm生物科学股份有限公司	Multivalent human immunodeficiency virus antigen binding molecules and uses thereof
ES2800034T3 (en)	2015-07-09	2020-12-23	Dispensing Tech Bv	System for dosed dispensing of a fluid and manufacturing method
CN108463472A (en)	2015-09-30	2018-08-28	Igm生物科学有限公司	The binding molecule of J- chains with modification
JP7065766B2 (en)	2015-09-30	2022-05-12	アイジーエムバイオサイエンシズインコーポレイテッド	Bonded molecule with modified J chain
EP3455257B1 (en)	2016-05-09	2021-09-22	IGM Biosciences Inc.	Anti-pd-l1 antibodies
CA3030634A1 (en)	2016-07-20	2018-01-25	Igm Biosciences, Inc.	Multimeric cd137/4-1bb binding molecules and uses thereof
MX2019000796A (en)	2016-07-20	2019-06-03	Igm Biosciences Inc	Multimeric ox40 binding molecules and uses thereof.
MX2019000799A (en) *	2016-07-20	2019-06-03	Igm Biosciences Inc	Multimeric gitr binding molecules and uses thereof.
WO2018017763A1 (en)	2016-07-20	2018-01-25	Igm Biosciences, Inc.	Multimeric cd40 binding molecules and uses thereof
JP2020512820A (en)	2017-04-07	2020-04-30	アイジーエムバイオサイエンシズインコーポレイテッド	Modified human IgM constant region for regulation of effector function of complement dependent cytolysis
KR20200123782A (en)	2018-02-26	2020-10-30	아이쥐엠 바이오사이언스 인코포레이티드	Use of multiple bonded anti-DR5 binding molecules in combination with chemotherapeutic agents for cancer treatment
BR112020017296A2 (en)	2018-03-01	2020-12-29	Igm Biosciences, Inc.	CHANGES OF IGM FC AND J CHAIN AFFECTING THE SERUM IGM SERIE LIFE
MX2021004660A (en) *	2018-10-23	2021-05-28	Igm Biosciences Inc	MULTIVALENT IgM- AND IgA-Fc-BASED BINDING MOLECULES.
WO2020163646A1 (en) *	2019-02-08	2020-08-13	Igm Biosciences, Inc.	Anti-gitr antigen-binding domains and uses thereof

2019
- 2019-03-01 BR BR112020017296-0A patent/BR112020017296A2/en unknown
- 2019-03-01 CA CA3091144A patent/CA3091144A1/en active Pending
- 2019-03-01 AU AU2019227984A patent/AU2019227984A1/en active Pending
- 2019-03-01 MX MX2020009069A patent/MX2020009069A/en unknown
- 2019-03-01 WO PCT/US2019/020374 patent/WO2019169314A1/en active Application Filing
- 2019-03-01 SG SG11202008343YA patent/SG11202008343YA/en unknown
- 2019-03-01 EP EP19760662.7A patent/EP3758752A4/en active Pending
- 2019-03-01 KR KR1020207023441A patent/KR102745232B1/en active Active
- 2019-03-01 CN CN201980016388.5A patent/CN111787951B/en active Active
- 2019-03-01 JP JP2020543995A patent/JP7376490B2/en active Active
2020
- 2020-03-23 US US16/827,100 patent/US10899835B2/en active Active
- 2020-08-09 IL IL276590A patent/IL276590A/en unknown
- 2020-12-03 US US17/110,550 patent/US20210087273A1/en not_active Abandoned
2023
- 2023-10-26 JP JP2023183845A patent/JP2024016093A/en active Pending
- 2023-12-29 US US18/400,974 patent/US20240124584A1/en active Pending

Also Published As

Publication number	Publication date
US20210087273A1 (en)	2021-03-25
CA3091144A1 (en)	2019-09-06
EP3758752A4 (en)	2021-12-15
BR112020017296A2 (en)	2020-12-29
JP2021514618A (en)	2021-06-17
CN111787951B (en)	2025-06-17
IL276590A (en)	2020-09-30
US10899835B2 (en)	2021-01-26
JP2024016093A (en)	2024-02-06
US20200239572A1 (en)	2020-07-30
CN111787951A (en)	2020-10-16
MX2020009069A (en)	2020-10-08
US20240124584A1 (en)	2024-04-18
KR20200128391A (en)	2020-11-12
KR102745232B1 (en)	2024-12-26
WO2019169314A1 (en)	2019-09-06
EP3758752A1 (en)	2021-01-06
JP7376490B2 (en)	2023-11-08
AU2019227984A1 (en)	2020-09-10

Publication	Publication Date	Title
IL276590A (en)	2020-09-30	Igm fc and j-chain mutations that affect igm serum half-life
IL278920A (en)	2021-01-31	Entpd2 antibodies, combination therapies, and methods of using the antibodies and combination therapies
EP3638320A4 (en)	2021-01-20	Igf-1r monoclonal antibodies and uses thereof
EP3466974A4 (en)	2020-05-13	Anti-human pd-1 humanized monoclonal antibody and use thereof
EP3470427A4 (en)	2020-03-04	Anti-human interleukin-17a monoclonal antibody, and preparation method and use thereof
EP3181587A4 (en)	2017-12-06	Anti-human il-17 monoclonal antibody and use thereof
EP3901172A4 (en)	2023-01-11	Humanized anti-pd-1 antibody and use thereof
SG11202012148RA (en)	2021-01-28	Monoclonal antibodies against human tim-3
EP3464355A4 (en)	2020-01-22	Dsg2 monoclonal antibody and use thereof
ZA201807132B (en)	2021-05-26	Humanized anti-basigin antibodies and the use thereof
LT3445785T (en)	2022-10-10	Humanized anti clever-1 antibodies and their use
EP3590964A4 (en)	2020-03-25	Improved anti-vegfr-2 monoclonal antibody
EP3785732A4 (en)	2022-02-23	Antibody against tim-3 and application thereof
EP3851456A4 (en)	2022-06-08	Anti-cd38 antibody, antigen-binding fragment thereof, and pharmaceutical use
KR101882087B1 (en)	2018-07-25	Monoclonal antibody against viral hemorrhagic septisemia virus and use thereof
EP3404042A4 (en)	2018-12-05	Monoclonal antibody fnab8 and application thereof
IL281608A (en)	2021-05-31	Anti-human cd45rc antibodies and uses thereof
EP3901171A4 (en)	2022-08-03	Anti-human tim-3 monoclonal antibody and application thereof
EP3774920A4 (en)	2022-01-05	Anti-pd-l1 antibodies and use thereof
GB201911211D0 (en)	2019-09-18	Monoclonal antibodies against ambra-1
GB201820006D0 (en)	2019-01-23	Humanised anti-IL17BR antibody
HK40033940A (en)	2021-04-16	Igm fc and j-chain mutations that affect igm serum half-life
HK40079408B (en)	2025-02-21	Humanized anti-claudin-1 antibodies and uses thereof
HK40043135B (en)	2025-02-14	Monoclonal antibodies against human tim-3
HK40054328A (en)	2022-02-18	Anti-human cd45rc antibodies and uses thereof